3ML5
Crystal structure of the C183S/C217S mutant of human CA VII in complex with acetazolamide
Summary for 3ML5
| Entry DOI | 10.2210/pdb3ml5/pdb |
| Descriptor | Carbonic anhydrase 7, ZINC ION, 5-ACETAMIDO-1,3,4-THIADIAZOLE-2-SULFONAMIDE, ... (4 entities in total) |
| Functional Keywords | protein-inhibitor complex, lyase |
| Biological source | Homo sapiens (human) |
| Cellular location | Cytoplasm (Probable): P43166 |
| Total number of polymer chains | 1 |
| Total formula weight | 30396.38 |
| Authors | Di Fiore, A.,Truppo, E.,Supuran, C.T.,Alterio, V.,Dathan, N.,Bootorabi, F.,Parkkila, S.,Monti, S.M.,De Simone, G. (deposition date: 2010-04-16, release date: 2011-03-02, Last modification date: 2024-10-09) |
| Primary citation | Di Fiore, A.,Truppo, E.,Supuran, C.T.,Alterio, V.,Dathan, N.,Bootorabi, F.,Parkkila, S.,Monti, S.M.,De Simone, G. Crystal structure of the C183S/C217S mutant of human CA VII in complex with acetazolamide Bioorg.Med.Chem.Lett., 20:5023-5026, 2010 Cited by PubMed Abstract: Human carbonic anhydrase VII (hCA VII) is a cytosolic member of the alpha-CA family. This enzyme is mainly localized in a number of brain tissues such as the cortex, hippocampus and thalamus and has been noted for its contribution in generating neuronal excitation and seizures. Recently, it has been also proposed that hCA VII may be involved in the control of neuropathic pain, thus its inhibition may offer a new approach in designing pain killers useful for combating neuropathic pain. We report here the X-ray crystallographic structure of a mutated form of human CA VII in complex with acetazolamide, a classical sulfonamide inhibitor. These crystallographic studies provide important implications for the rational drug design of selective CA inhibitors with clinical applications. PubMed: 20688517DOI: 10.1016/j.bmcl.2010.07.051 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.05 Å) |
Structure validation
Download full validation report
